Finding new antifungal peptides to fight infections.
Official title: Accelerating the Discovery of Antifungal Peptides with OBOC Combinatorial Technology.
Funded at University of California at Davis · NIH-11220151 · Data updated 2026-11-12
This study is working on finding new medicines to help fight serious fungal infections that can make people sick, using a special method to create and test tiny pieces of proteins that can target the fungi without harming healthy cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | January 2, 2025 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $642,775 |
| NIH project number | 1R56AI180052-01A1 |
| Project ID | NIH-11220151 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from invasive fungal infections or those at high risk for such infections, particularly immunocompromised patients.
✕Less likely to help
Patients with fungal infections that are already effectively treated by existing antifungal medications may not benefit from this research.
What this research studies
This research focuses on developing new antifungal agents to combat serious fungal infections that pose a significant threat to human health. By utilizing a technique called one-bead one-compound (OBOC) combinatorial technology, the researchers will create and screen a library of synthetic peptides to identify those that effectively target fungal cells while sparing human cells. The study employs advanced screening methods to rapidly assess the effectiveness and safety of these peptides, aiming to discover novel treatments for infections caused by fungi like Aspergillus and Candida species.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antifungal treatments that are more effective and have fewer side effects than current options.
How similar studies have gone: Previous research has shown promise in developing antifungal peptides, but this approach using OBOC technology is relatively novel and has not been extensively tested.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Gelli, Angie — University of California at Davis
- Study coordinator: Gelli, Angie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.